| Vasculitis in Clinical Practice | 2 |
|---|
| Preface | 4 |
| Contents | 5 |
| Contributors | 16 |
| Abbreviations | 17 |
| Part 1: Introduction | 19 |
| Chapter 1: Definitions | 20 |
| 1.1 General Introduction | 20 |
| 1.2 Definitions | 21 |
| Chapter 2: Classification and Epidemiology | 24 |
| 2.1 Introduction | 24 |
| 2.2 ACR (1990) Criteria | 25 |
| 2.3 Chapel Hill Consensus Definitions | 26 |
| 2.4 Epidemiology | 26 |
| 2.5 Etiological Factors | 27 |
| Key Points | 28 |
| References | 28 |
| Chapter 3: General Presentation of the Vasculitides | 29 |
| 3.1 Introduction | 29 |
| 3.2 Pattern Recognition | 29 |
| 3.3 Laboratory Investigations | 32 |
| 3.4 Differential Diagnosis | 34 |
| Key Points | 34 |
| References | 35 |
| Chapter 4: General Principles of Treatment | 36 |
| 4.1 Treatment | 36 |
| 4.2 Remission Induction | 36 |
| 4.2.1 Large Vessel Disease | 37 |
| 4.2.2 Medium Vessel Disease | 37 |
| 4.2.3 Medium/Small Vessel Vasculitis | 37 |
| 4.2.4 Small Vessel Vasculitis | 39 |
| 4.3 Maintenance Therapy | 40 |
| 4.4 Long-Term Follow-Up | 40 |
| 4.5 Relapsing Disease | 40 |
| 4.6 Refractory Disease | 41 |
| 4.7 Specific Drugs Used to Treat Vasculitis | 42 |
| 4.7.1 Cyclophosphamide | 42 |
| 4.7.2 Glucocorticoids | 43 |
| 4.7.3 Methotrexate | 43 |
| 4.7.4 Plasma Exchange | 44 |
| 4.8 Monitoring | 44 |
| 4.9 Patient Advice | 45 |
| 4.10 Detection and Prevention of the Adverse Effects of Therapy | 45 |
| 4.10.1 Osteoporosis | 45 |
| 4.10.2 Vaccinations | 46 |
| 4.10.3 Pneumocystis Jirovecii Infection | 46 |
| 4.10.4 Cyclophosphamide-Induced Bladder Toxicity | 46 |
| Key Points | 46 |
| References | 47 |
| Part 2: Features of Individual Diseases | 48 |
| Chapter 5: Giant Cell Arteritis | 49 |
| 5.1 Introduction | 49 |
| 5.2 Definition and Classification | 49 |
| 5.3 Epidemiology | 50 |
| 5.4 Etiology | 50 |
| 5.5 Clinical Features | 51 |
| 5.5.1 Systemic | 51 |
| 5.5.2 Craniofacial | 51 |
| 5.5.3 Ophthalmic | 53 |
| 5.5.4 Neurologic | 53 |
| 5.5.5 Extracranial Artery | 53
|